New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
13:19 EDTRGDXResponse Genetics to serve as molecular screening center for ALCHEMIST
Response Genetics (RGDX) announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST. ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network of the National Cancer Institute, or NCI, a screening trial and two associated treatment trials. The research subcontract was awarded by Leidos Biomedical Research (LDOS).
News For RGDX From The Last 14 Days
Check below for free stories on RGDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RGDX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use